Source: Eur Respir J 2016; 48: 1242-1245



Rating:

Share or cite this content

Citations should be made in the following way:
Hijdra Daniëlle, Vorselaars Adriane D.M., Crommelin Heleen A., van Moorsel Coline H.M., Meek Bob, Claessen Anke M.E., Rijkers Ger T., Grutters Jan C.. Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?. Eur Respir J 2016; 48: 1242-1245

Member's Comments

No comment yet.

Related content which might interest you: Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Do kinetics of interferon-gamma responses predict TB relapse? Source: Annual Congress 2011 - Risk assessment for tuberculosis Year: 2011 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Is there any clinical application for determining the serum cytokines profile in sarcoid patients? Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Can genomic signatures predict response to systemic therapy? Source: Annual Congress 2013 –Biological signatures in thoracic oncology Year: 2013 Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Improvement of the clinical response to infiximab in refractory sarcoidosis by reducing the dose interval Source: Eur Respir J 2007; 30: Suppl. 51, 245s Year: 2007 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008 Our approach about latent tuberculosis infection in patients who are given anti-TNF alpha therapy Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009